Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600121689) titled 'A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Anti-tumor Efficacy of HDM2024 in Participants With Advanced Solid Tumors' on April 1.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Shanghai East Hospital

Condition: Advanced Solid Tumors

Recruitment Status: Not Recruiting

Phase: 1

Date of First Enrollment: 2026-04-01

Target Sample Size: Treatment:63;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=316335

Published by HT Digital Content Services with permissi...